SCHEMBL4462587

SCHEMBL4462587

Cc1c(O)c(/C=C/c2ccc3ccccc3n2)c(C)c2c1CCC1(CCC1)O2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.39
MAPT P10636 7/20 0.39
RAB9A P51151 7/20 0.39
LMNA P02545 6/20 0.39
NPC1 O15118 6/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
L3MBTL1 Q9Y468 4/20 0.39
TDP1 Q9NUW8 3/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
ECE2 P0DPD6 2/20 0.39
HTT P42858 2/20 0.39
TP53 P04637 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYSLTR2 Q9NS75 2/20 0.37
CYSLTR1 Q9Y271 2/20 0.37
PKM P14618 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37
PSMD14 O00487 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4470237 1.00 KDM4E (0.39) KDM4EMAPTRAB9ALMNANPC1
SCHEMBL4462592 1.00 KDM4E (0.39) KDM4EMAPTRAB9ALMNANPC1
SCHEMBL4464106 0.92 KDM4E (0.39) KDM4EMAPTRAB9ALMNANPC1
SCHEMBL4464108 0.92 KDM4E (0.39) KDM4EMAPTRAB9ALMNANPC1
SCHEMBL4468647 0.76 MEN1 (0.37) KDM4EMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL13756700 0.71 BCHE (0.37) KDM4EMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL4469890 0.69 CYSLTR1 (0.42) CYSLTR2CYSLTR1PDE10A
SCHEMBL4471043 0.68 CYP3A4 (0.58) MAPTLMNATDP1MEN1KMT2A
SCHEMBL4472749 0.64 CYP3A4 (0.43) MAPTLMNATDP1MEN1KMT2A
SCHEMBL28443608 0.64 RAB9A (0.80) KDM4EMAPTRAB9ALMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
EP-1836183-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS Galileo Pharmaceuticals, Inc. (US) 2007-09-26 EP disclosed
WO-2006065686-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS GALILEO PHARMACEUTICALS, INC. (US) 2006-06-22 WO disclosed
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors ALOX15B, ALOX5, ALOX15 KDM4E 3310/4885MAPT 4822/4885RAB9A 3169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.